Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
365 hedge funds and large institutions have $2.2B invested in Catalyst Pharmaceutical in 2025 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 158 increasing their positions, 125 reducing their positions, and 48 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 158 | Existing positions reduced: 125
2.08% more ownership
Funds ownership: 81% → 83.09% (+2.1%)
2% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 48
2% less funds holding
Funds holding: 371 → 365 (-6)
8% less capital invested
Capital invested by funds: $2.39B → $2.2B (-$190M)
67% less funds holding in top 10
Funds holding in top 10: 6 → 2 (-4)
94% less call options, than puts
Call options by funds: $403K | Put options by funds: $6.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
+$29.1M |
| 2 |
Morgan Stanley
New York
|
+$18.6M |
| 3 |
Fundsmith LLP
London,
United Kingdom
|
+$13.2M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$13.1M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$17.1M |
| 2 |
DM
Deerfield Management
New York
|
-$12.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$10M |
| 4 |
NVCHI
New Vernon Capital Holdings II
Morristown,
New Jersey
|
-$7.42M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$6.61M |
CPRX Hedge Fund Activity: Q2 2025 in Review
365 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2025, worth a combined $2.2B — down 8% from $2.39B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new CPRX positions and 48 closed out — a net gain of 1 holder — while 158 added to existing stakes and 125 trimmed.
The largest buyer was American Century Companies, adding an estimated $29.1M. The largest seller was Goldman Sachs, cutting an estimated $17.1M.
- 365 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2025, down from 371 in Q1 2025.
- Funds reported $2.2B of Catalyst Pharmaceutical stock for Q2 2025, down 8% quarter-over-quarter.
- 49 funds opened new Catalyst Pharmaceutical positions in Q2 2025 and 48 closed out, a net change of +1 holder.
- The largest Catalyst Pharmaceutical buyer in Q2 2025 was American Century Companies, an estimated $29.1M added.
- The largest Catalyst Pharmaceutical seller in Q2 2025 was Goldman Sachs, an estimated $17.1M sold.
Based on aggregated 13F filings for Q2 2025.